 The comparator for this study will be a placebo. Patients randomized both to the control group and those randomized to the intervention group will receive standard of care postoperatively, which will include pain control with scheduled acetaminophen and pro re nata oral and subcutaneous hydromorphone. In addition, control patients will receive a placebo with the same scheduling as the study drug, ketorolac. The rationale for this choice is to limit potential sources of bias, such as the patient and her care team, and maximize the accuracy of the primary outcome and patient-completed questionnaires that will serve as a secondary outcome. Other authors have previously successfully used placebos for ketorolac in their study design. 